In brief: BresaGen, Premier Bionics, Panbio, Eqitx
Friday, 03 February, 2006
BresaGen has concluded an agreement with Indian firm BV BioCorp, to register and distribute BresaGen's G-CSF for leukaemia and an undisclosed product in India, Sri Lanka, Bangladesh, and Nepal. Details of the agreement are confidential, but BresaGen anticipates the projects will be developed and clinical trials for registration will commence in early 2007.
Medic Vision, a wholly owned subsidiary of Premier Bionics (ASX:PBI) has signed a contract with German company VR Magic for the sale and distribution of the Eyesis Ophthalmossurgical Simulator, which provides training for vitreo-retinal and cataract surgery, in Australia and New Zealand with rights to sell into the Asia Pacific region.
Panbio (ASX:PBO) has appointed Peter Arnison, a former governor of Queensland, as the company's new chairman.
Dr Nick Ede has resigned from his position as chief operating officer and general manager of Eqitx (ASX:EQX) subsidiary ZingoTX to pursue other career options.
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
Dopamine helps our brains to let go of memories
In a discovery that could reshape how we think about memory, researchers at Flinders University...
Vaccine for elephant herpesvirus found to be safe
The vaccine could prevent deadly elephant endotheliotropic herpesvirus in calves — the...
